ALS is a progressive disorder of the nervous system causing weakness in muscles, including those controlling swallowing and breathing. For the majority of people, weakness tends to progress, causing death in three to five years.
People with ALS have been interested in lithium as a treatment after promising results were reported from a small Italian study.
The current study, also conducted in Italy, was stopped early due to an extremely high dropout rate from death, serious side effects and lack of benefit.
The study involved 171 people with ALS. One group of 87 people received a dosage of lithium considered to be therapeutic. The other group of 84 people received a dosage of lithium that was subtherapeutic, or lower than approved uses of lithium.
There was no difference between the two groups in how long the participants lived, how long until they were severely disabled or how well they were able to function with activities such as walking and swallowing. Of the 171 people, 117 or 68 percent had dropped out of the study due to death, side effects or because they thought the drug was ineffective.
“This discontinuation rate is two times higher than that in other recent studies for ALS drugs,” said study author Adriano Chiò, MD, of the University of Turin in Italy and a member of the American Academy of Neurology. “This high dropout level, along with the relatively high frequency of side effects, raises serious doubts about the safety of this drug and also shows it to be ineffective for people with ALS.”
ALS expert Carmel Armon, MD, MHS, of Tufts University School of Medicine and Baystate Medical Center in Springfield, Mass., points out in an accompanying editorial that this study did not use a true placebo. Two additional studies in progress that have some participants taking a placebo may provide the definitive answer on whether lithium is effective in ALS, he said.
The study was supported by the Italian National Health System.
The American Academy of Neurology, an association of more than 22,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as multiple sclerosis, restless legs syndrome, Alzheimer’s disease, narcolepsy and stroke.
For more information about the American Academy of Neurology, visit http://www.aan.com.VIDEO: http://www.youtube.com/AANChannel
Rachel L. Seroka | American Academy of Neurology
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences